cyrilzakka/clinical-trials huggingface dataset:
Use of Allograft Cartilage in Cosmetic and Reconstructive Rhinoplasty

This is a single-center, blinded, controlled trial, conducted in healthy adult subjects undergoing a reconstructive or cosmetic rhinoplasty involving the use of cartilaginous graft (either non-irradiated cartilage sheet allograft compared to autologous harvest and grafting of costal cartilage).


Eligibility Criteria:
Inclusion Criteria:

* Subject is scheduled to undergo a reconstructive or cosmetic surgical procedure to alter the appearance of the nose that is anticipated to require a cartilage graft.
* Subject is willing to sign an informed consent.
* Subject is a non-smoker or has stopped smoking at least 6-weeks prior to inclusion in the study.
* Subjects must agree to forgo any treatment, medical or non-medical, to the area treated in this study, for the duration of the 1-year post-treatment evaluation period, unless there is prior approval from the investigator.

Exclusion Criteria:

* Presence of significant endocrine, immunologic, dermatologic or psychiatric abnormalities that would render the subject an inappropriate candidate for the study.
* Presence of any malignancy not considered cured in the midface area specifically (no evidence of cancer recurrence in the previous five years).
* History of radiation to the area(s) to be treated in the study.
* Subjects taking chronic steroids (injected or oral) or other immune modulators.
* Subjects with a history of skin sensitivity (dermatitis) to either the suture materials or dressings to be utilized during the course of this study.
* Subjects with skin conditions that could result in poor healing or widened scars.
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years
* Diagnosis of newly diagnosed or recurrent GBM with plan to initiate treatment with TTFields with or without systemic therapy, confirmed by the enrolling institution
* Able to self-administer topical interventions or has available another person who can apply the topical agents
* Treatment with TTF should be initiated within 7 days of planned initiation on this trial.

Exclusion Criteria:

* Known history of allergy to any ingredient of the study agents
* Preexisting scalp disorders such as psoriasis or dermatitis that, in the opinion of the investigator, will affect the grading of skin adverse events, confirmed by enrolling institution.
* Use of concurrent topical therapy to the scalp for another dermatologic condition
* Active, uncontrolled infection requiring systemic or oral antibiotic therapy within 14 days of enrollment
* Use of greater than 4 mg dexamethasone a day within 14 days of enrollment
* Malignant glioma
* Pregnant Women
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.

The proposed biospecimen repository would be derived from patients diagnosed with ILD. This is to include 500 patients in the repository, with each patient contributing one blood sample. Patients with pneumonia and healthy patients will also be recruited as a control group.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia
* Patients willing to provide written informed consent

Exclusion Criteria:

* Unwillingness/unable to give blood samples
Accuracy of Endoscopists in Predicting Polyp Pathology

The study purpose is to assess the accuracy of experienced endoscopists at a community hospital in predicting histological types of polyps resected at colonoscopy using white light. Patients 50 years or older undergoing first-time screening colonoscopy will be included in this observational study.

The study purpose is to assess the accuracy of experienced endoscopists at a community hospital in predicting histological types of polyps resected at colonoscopy using white light. The study will be conducted at Good Samaritan Hospital and TriHealth Surgery Center West. Study participants include patients 50 years or older undergoing first-time screening colonoscopy. This is an observational study and does not involve any patient interventions. After completing the colonoscopy, the endoscopist will document their prediction of the polyp type. The polyp type predicted by the endoscopist will be compared to the polyp type documented in the pathology report to determine accuracy. It is estimated that study enrollment will take 6 months.

Eligibility Criteria:
Inclusion Criteria:

* Males and females

Exclusion Criteria:

* first degree relative diagnosed with colorectal carcinoma at age 59 or under
* New onset of iron deficiency anemia (within past 3 months)
* Abnormal imaging of colon within past 3 months
* Pregnant women
* Inadequate visualization reported by endoscopist
The Effect of UV-Irradiation on Cutaneous Cicatrices

The purpose of this study is to examine the effect of UV-irradiation on human cutaneous cicatrices by clinical examinations and histological, immunohistochemical and biochemical analyses.


Eligibility Criteria:
Inclusion Criteria:

* Non-smoking volunteers,
* Skintypes II or III

Exclusion Criteria:

* Atopic dermatitis,
* Tendency to produce keloids or hypertrophic scars,
* Exposure of UV light during the last 3 months,
* Medical treatment
Osseodensification Versus Conventional Drilling Effect on Implant Stability

A total of 80 implants were placed in the posterior region of the maxilla in 40 patients in a split-mouth design. Bone quality was classified into type I, II, III, IV, or V as assessed preoperatively on cone-beam computed tomography (CBCT) . Primary implant stability was measured with insertion torque and resonance frequency analysis (ISQ values). Secondary stability was measured by ISQ at abutment installation.


Eligibility Criteria:
Inclusion Criteria:

* (a) Bilateral edentulism in the maxillary posterior region dating back more than 6 months,
* (b) sufficient bone height (distance between the bone crest and maxillary sinus \>8 mm) and width at the alveolar crest (≥6 mm) that would not necessitate bone augmentation,
* (c) at least 2 mm vestibular keratinized mucosa width and 3 mm mucosa thickness,
* (d) full-mouth plaque and bleeding scores \<20%.

Exclusion Criteria:

* patients with systemic diseases, conditions, or used medications having the potential to impair surgery, bone, and wound healing dynamics (such as diabetes) will be excluded.
* patients who are allergic to antibiotics and non-steroidal anti-inflammatory drugs
* bone height \<8mm
* ridge and soft tissue deficiencies requiring augmentation procedures and
* endodontic or periodontal lesions neighboring the edentulous sites will be also excluded.
An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study

The purpose of this study is to find out if hyaluronan, an injectable medication for knee arthritis, also works for arthritis at the base of the thumb. This study will also evaluate how good ultrasound is at visualizing medication in the thumb joint. We are no longer recruiting for this part of the open label trial.


Eligibility Criteria:
Inclusion Criteria:

* Radiographic evidence of at least moderate narrowing (joint space \< 1mm) or the presence of osteophytes or sclerosis at the Carpometacarpal joint
* Patient complaint of unacceptable pain despite modification of activity, a trial of splinting and a therapeutic dose of NSAIDS
* If bilateral disease, only the most severely involved hand, (as defined by VAS for pain), will be entered in the study.
* Proficiency in English.

Exclusion Criteria:

* Previous bad injury to the thumb
* Previous hand surgery on the study thumb
* Known hand comorbidities (i.e. carpal tunnel syndrome, de Quervains Tenosynovitis etc)
* Rheumatoid arthritis or lupus
* Bleeding problems
* Being on blood thinners (except aspirin)
* Known allergies to any of the medications being used
* Allergies to chicken products
* Current use of oral steroids
* Cancer that is not cured or in remission
* Severe diabetes
* A serious infection somewhere else in the subject's body
Impact Hesperetin in Combination with Sucrose on Blood Glucose Regulation

The aim of this cross-over intervention study is to investigate the influence of hesperetin applied in combination with sucrose in comparison to an equally sweet-tasting sucrose-only solution and an isocaloric sucrose-only solution on markers of energy metabolism

The study is designed as a randomised cross-over intervention study with three arms. The aim is to investigate the influence of a 10% sucrose solution, corresponding to the sugar content of a conventional soft drink, compared to an equally sweet-tasting 7% sucrose solution in combination with 50 mg/L of the polyphenol hesperetin, and a less sweet 7% sucrose solution w/o hesperetin on time-dependent blood glucose fluctuations and ad libitum energy intake in metabolically healthy male volunteers.

To investigate the underlying mechanisms, the individual appetite score, metabolic and hormonal responses to the interventions and will be measured. In addition, the participants' individual thresholds for sweet taste, preference and consumption for sweet-tasting foods such as sugar and sweeteners, and their body composition will be recorded as potential influencing factors.

Eligibility Criteria:
Inclusion Criteria:

* healthy
* non-smoking
* normal taste responses towards sweet taste

Exclusion Criteria:

* pregnancy or breast-feeding
* regular smokers
* disturbed glucose and/or lipid metabolism
* regular intake of medication
* known allergies against one of the test compounds
* ageusia alcohol or drug addiction intake of antibiotics within the past 2 months
Dapagliflozin Patient Satisfaction Survey

The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus

This is a cross-sectional, observational patient survey study. Study subjects will be adult commercial members of the large US health plan affiliated with Optum with evidence of T2D initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey mailing.

Eligibility Criteria:
Inclusion Criteria:

* At least one pharmacy claim for dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for an SGLT2 medication during the 6 months prior to sample identification.
* Evidence of T2D diagnosis.
* Age ≥18 as of the drug index date.
* 6 months of continuous enrollment in a commercial health plan with both pharmacy and medical benefits during the identification period through the patient interview sample identification date.
* Self-reported T2D diagnosis during the patient interview.

Exclusion Criteria:

* Patients with evidence of type 1 diabetes mellitus and unknown type
* Patients who are pregnant
Trial of Unicompartmental Versus Total Knee Arthroplasty

This study is a prospective, randomized trial to compare patient outcomes of unicompartmental knee arthroplasty (UKA) and total knee arthroplasty (TKA) for the treatment of medial compartment osteoarthritis.


Eligibility Criteria:
Inclusion Criteria:

* medial compartment osteoarthritis of the knee
* knee flexion greater than greater than 90 degrees
* flexion contracture of less than 10 degrees
* varus deformity \< 20 degrees
* grade IV degeneration of the medial compartment

Exclusion Criteria:

* lateral compartment degenerative changes
* previous lateral meniscectomy
* anterior cruciate ligament deficiency
* body mass index \> 40
* inflammatory arthritis
* history of septic arthritis
* hemoglobin A1c \> 8.0
* chronic liver disease
* stage 3A or greater chronic renal disease
* active IV drug abuse
* patients requiring thromboembolic prophylaxis
Clinical Impact of the IBox As an Early Intervention TooL

International, multicentre, randomized 1:1 controlled trial to prove the clinical and medico economic benefits of the medical device Predigraft, by showing that the use of Predigraft could improve patient's follow-up.

The study aims to demonstrate improvement of the prevalence of biopsies leading to therapeutic change in the Predigraft group compared to the Standard of care group in kidney transplanted patients.

It is hypothesized that using Predigraft as a monitoring tool will help the physician detect earlier and more often abnormalities with the patient allograft. This should lead to an increased number of biopsies leading to therapeutic change. These biopsies should be performed earlier than without the iBox monitoring tool. This would improve long-term allograft function, kidney allograft and patient survival.

Eligibility Criteria:
Inclusion Criteria:

* Men and women, age ≥ 18 years old at the time of consent.
* Patients receiving a living or deceased donor kidney allograft.
* Patients transplanted at least 3 months before inclusion.
* Patients who signed the informed consent form and are willing to comply with study procedures.

Exclusion Criteria:

* Combined transplant (i.e. heart-kidney, liver-kidney).
* Patients who are unable or unwilling to comply with study procedures.
* Vulnerable patients (minors, protected adults, legally detained).
* Patients participating in other interventional studies.
Immediate Effects of Posterior Mobilization Versus Caudal Mobilization in Patients With Temporomandibular Disorders

The Temporomandibular Joint (TMJ) is one of the most complex joints in the individual. It is composed of the mandibular condyle is positioned within the glenoid fossa of the temporal bone, and the articular disk that separates these two bones. The normal biomechanics of the TMJ is the concave / convex relationship between the condyles and the articular disc. The movements of the TMJ joint are: mandibular depression and elevation (opening and closing of the mouth), mandibular protrusion and retraction, and lateral deviations. The DTM is a musculoskeletal disorder of the masticatory system that affects over 25% of the population. Physical therapy can be adopted this treatment in order to relieve musculoskeletal pain, reduce inflammation and restore normal motor functions. The physical therapy interventions taken include electrotherapy, exercise therapy, acupuncture and manual therapy. Overall objective is to assess the immediate effects of previous mobilization versus flow amplitude of mandibular depression in patients with temporomandibular dysfunction. The type of study will be a randomized study of two parallel groups balanced distribution (1: 1) and double-blind. The research will be conducted in the Laboratory of Human Movement Analysis of Physiotherapy, Faculty of Medicine, Federal University of Ceará. The study population will consist of residents in the city of Fortaleza-CE individuals who voluntarily seek to participate in the study due to symptoms of TMD. Data, anthropometry, application of Research Diagnostic Criteria for Temporomandibular Disorders will be collected. The physiotherapist responsible for the assessment before and after the interventions will be blind with respect to the distribution of the treatment groups. The patient will also be blind, because you will not know whether or caudal anterior mobilization was performed. Randomization codes are generated by computer using Random Allocation Software (version 1.0.0) at a ratio of 1: 1 by a researcher not involved in the data collection. These codes will be placed in sealed, opaque envelopes being numbered consecutively, which will ensure the covert allocation of study participants. Our data are considered confidential as joint property of the parties involved.


Eligibility Criteria:
Inclusion Criteria:

* Individuals have not received the last 3 months treatment for TMD, who are not taking anti-inflammatory and / or analgesic for at least two weeks, you are not in the period of postoperative head and / or neck and to accept the participation in the study and signed the Instrument of Consent

Exclusion Criteria:

* Subjects with no teeth, history of metabolic diseases (such as hyper / hypothyroidism), neurological disorders, history of cancer in the last five years, active inflammatory arthritis, fractures, dislocations of the jaw or neck.
Interval Between Neoadjuvant Therapy and Surgery in the Treatment of Locally Advanced Rectal Cancer (CRONOS)

The investigators evaluate the response of rectal cancer to neoadjuvant therapy and classify the response according to specific periods of time after the end of neoadjuvant treatment.

In the treatment of locally advanced rectal cancer, an optimal interval between neoadjuvant therapy and surgery might improve oncological outcomes. Besides, those patients who achieve a good response might benefit from active surveillance, avoiding surgical comorbidities. This optimal interval is yet to be defined. This study will aim to better define the role of time interval between the end of neoadjuvant therapy (NAT) and TME in Spanish regions, together with analyzing the importance of restaging MRI and define the basis for implementing a "watch and wait" protocol.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients suitable for elective surgical resection of biopsy-confirmed rectal adenocarcinoma (0-15 cm from the anal verge) determined by rectal cancer protocol magnetic resonance imaging.
* Patients treated with long-course neoadjuvant chemoradiotherapy (nCRT).
* Patients treated with short-course radiotherapy with delayed surgery.
* Clinical stage IIA, IIB, IIIA, IIIB, IIIC (cT3/cT4, or cN1/cN2 with any cT, M0) determined by rectal cancer protocol magnetic resonance imaging

Exclusion Criteria:

* Intolerance or contraindication to planned NAT.
* Patients who have not finished NAT for any reason.
* Patients with unknown cT or cM.
* Tumors previously treated with local excision or with distant metastatic disease.
Phase 4 Field Trial of the Unicirc Instrument With Tissue Adhesive

This is a field trial of the Unicirc instrument to excise the foreskin, plus use of cyanoacrylate tissue adhesive to seal the wound.


Eligibility Criteria:
Inclusion Criteria:

* Men at least 18 years of age

Exclusion Criteria:

* Poor general health
* Anatomical abnormalities that would complicate circumcision
* Bleeding disorder
* Ongoing infection
* Cannot attend followup visits
Clinical Trial of Ultrasound Combined With Computed Tomography Guided Lumbar Sympathetic Ganglion Block

To evaluate the safety and efficacy of ultrasound combined with CT-guided sympathetic ganglion block for refractory pain caused by sympathetic neuropathy of the lower extremities.

To evaluate the safety and efficacy of ultrasound combined with CT-guided sympathetic ganglion block for refractory pain caused by sympathetic neuropathy of the lower extremities. Patients with lumbar sympathetic block were enrolled and randomized to a conventional CT-guided group and an ultrasound-guided CT-guided group. By comparing the traditional CT guided and ultrasound combined with CT guided two programs, the radiation dose, block success rate, treatment time, etc. received by patients with lumbar sympathetic block were observed to understand whether ultrasound combined with CT guidance is a way to reduce radiation exposure. Under the premise of the dose, the method of blocking the success rate can still be guaranteed.

Eligibility Criteria:
Inclusion Criteria:

1.18\~80 years old; 2.Pain disorders requiring lumbar sympathetic block（Such as,Lower limb vascular disfunction,Diabetic polyneuropathy,Postherpetic neuralgia,Complex regional pain syndrome I and II,Cancer related neuropathic pain including Peripheral neuropathy caused by chemotherapy or other lower extremity sympathetic neuropathy）,conservative treatment for 3 months or longer can not be cured; 3.Numerical rating score≥4.

Exclusion Criteria:

1. Body mass index\> 30 kg / m2;
2. History of internal fixation in posterior lumbar laminectomy or any serious anatomic variation, such as scoliosis and tumors;
3. History of lumbar sympathetic neurochemistry or thermal neurolysis;
4. Pregnancy;
5. The puncture site is infected;
6. Coagulation dysfunction;
7. Allergic to local anesthetic or contrast agent;
8. Cognitive impairment or inability to provide informed consent.
Screening for Colorectal Neoplasm in First Degree Relatives of the Affected

To determine the prevalence of colorectal neoplasms in first degree relatives of those affected with sporadic colorectal cancer using colonoscopy as a screening tool. The prevalence will be compared to that of a defined matched cohort.

Colorectal cancer is a second commonest tumor in Hong Kong and the second commonest cause of cancer related death. About 1 in 23 males will develop colorectal cancer in his life time. The disease tends to cluster in families. This may be a combination of factors including shared genes, shared environment or chance. Known familial syndromes occur in only about 5% of cases. The majority is not well understood and labelled sporadic colorectal cancer. The screening strategy in families of subjects with colorectal cancer has not been defined. Colonoscopy is among the most sensitive and specific screening tool for colorectal neoplasm. The current study determines the prevalence of adenomas among first degree relatives of patients diagnosed with colorectal cancer. To quantify risk in this cohort, a case control analysis is used. The prevalence of the cohort is compared to that of a control population. The control group consists of relatives of patients with normal colonoscopic findings during the same study period.

Eligibility Criteria:
Inclusion Criteria:

* First degree relatives (age \>40 and \<70) of individuals affected with sporadic colorectal cancer (those not associated with inflammatory bowel disease, familial adenomatous polyposis or HNPCC syndrome).

Exclusion Criteria:

* A family history compatible with that of Hereditary Non-polyposis Colon Cancer (HNPCC) based on the Amsterdam criteria \[Table 5\].
* Known Familial Adenomatous Polyposis (FAP) syndrome
* Patients and relatives with known inflammatory bowel disease
* Relatives that have received colonoscopy examinations in the past 5 years \[details of colonoscopic examinations will be sought and information on colonic neoplasms recorded\]. Those who have had barium enema examinations are eligible for trial inclusion as barium examinations often have low sensitivity and specificity for adenomas (around 70% respectively)
* Severe cardio-pulmonary or other medical co-morbidities that preclude safe colonoscopic examination